BLACK DIAMOND THERAPEUTICS, INC. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
BLACK DIAMOND THERAPEUTICS, INC. (BDTX) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $1.51 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-05
- BLACK DIAMOND THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $1.51M, a 14.97% decline year-over-year.
- BLACK DIAMOND THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $1.45M, a 14.88% decline year-over-year.
- BLACK DIAMOND THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $1.74M, a 12.70% decline year-over-year.
- BLACK DIAMOND THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $1.78M, a 66.38% decline year-over-year.
- BLACK DIAMOND THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $6.63M, a 37.63% decline from fiscal 2024.
- BLACK DIAMOND THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $10.63M, a 10.65% increase from fiscal 2023.
- BLACK DIAMOND THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $9.60M, a 21.26% decline from fiscal 2022.
- BLACK DIAMOND THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $12.20M, a 13.11% decline from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.51M 10-Q · filed 2026-08-05 | $2.96M derived: sum of 2 quarters · filed 2026-08-05 | ||
| 2026-03-31 | $1.45M 10-Q · filed 2026-08-05 | |||
| 2025-12-31 | $6.63M 10-K · filed 2026-03-16 | |||
| 2025-09-30 | $1.74M 10-Q · filed 2025-11-06 | $3.52M derived: sum of 2 quarters · filed 2026-08-05 | $5.22M derived: sum of 3 quarters · filed 2026-08-05 | |
| 2025-06-30 | $1.78M 10-Q · filed 2026-08-05 | $3.48M derived: sum of 2 quarters · filed 2026-08-05 | ||
| 2025-03-31 | $1.70M 10-Q · filed 2026-08-05 | |||
| 2024-12-31 | $10.63M 10-K · filed 2026-03-16 | |||
| 2024-09-30 | $1.99M 10-Q · filed 2025-11-06 | $7.28M derived: sum of 2 quarters · filed 2025-11-06 | $8.99M derived: sum of 3 quarters · filed 2025-11-06 | |
| 2024-06-30 | $5.29M 10-Q · filed 2025-11-06 | $7.00M derived: sum of 2 quarters · filed 2025-11-06 | ||
| 2024-03-31 | $1.71M 10-Q · filed 2025-11-06 | |||
| 2023-12-31 | $9.60M 10-K · filed 2025-03-06 | |||
| 2023-09-30 | $2.75M 10-Q · filed 2024-11-05 | $5.40M derived: sum of 2 quarters · filed 2024-11-05 | $8.07M derived: sum of 3 quarters · filed 2024-11-05 | |
| 2023-06-30 | $2.65M 10-Q · filed 2024-11-05 | $5.32M derived: sum of 2 quarters · filed 2024-11-05 | ||
| 2023-03-31 | $2.67M 10-Q · filed 2024-11-05 | |||
| 2022-12-31 | $12.20M 10-K · filed 2024-03-12 | |||
| 2022-09-30 | $2.66M 10-Q · filed 2023-11-06 | $5.92M derived: sum of 2 quarters · filed 2023-11-06 | $9.29M derived: sum of 3 quarters · filed 2023-11-06 | |
| 2022-06-30 | $3.25M 10-Q · filed 2023-11-06 | $6.63M derived: sum of 2 quarters · filed 2023-11-06 | ||
| 2022-03-31 | $3.38M 10-Q · filed 2023-11-06 | |||
| 2021-12-31 | $14.04M 10-K · filed 2023-03-09 | |||
| 2021-09-30 | $3.01M 10-Q · filed 2022-11-08 | $7.57M derived: sum of 2 quarters · filed 2022-11-08 | $10.66M derived: sum of 3 quarters · filed 2022-11-08 | |
| 2021-06-30 | $4.56M 10-Q · filed 2022-11-08 | $7.65M derived: sum of 2 quarters · filed 2022-11-08 | ||
| 2021-03-31 | $3.09M 10-Q · filed 2022-11-08 | |||
| 2020-12-31 | $7.76M 10-K · filed 2022-03-17 | |||
| 2020-09-30 | $2.00M 10-Q · filed 2021-11-08 | $3.42M derived: sum of 2 quarters · filed 2021-11-08 | $5.29M derived: sum of 3 quarters · filed 2021-11-08 | |
| 2020-06-30 | $1.42M 10-Q · filed 2021-11-08 | $3.30M derived: sum of 2 quarters · filed 2021-11-08 | ||
| 2020-03-31 | $1.88M 10-Q · filed 2021-11-08 | |||
| 2019-12-31 | $3.64M 10-K · filed 2021-03-25 | |||
| 2019-09-30 | $850.00K 10-Q · filed 2020-11-10 | $1.04M derived: sum of 2 quarters · filed 2020-11-10 | $1.13M derived: sum of 3 quarters · filed 2020-11-10 | |
| 2019-06-30 | $192.00K 10-Q · filed 2020-11-10 | $283.00K derived: sum of 2 quarters · filed 2020-11-10 | ||
| 2019-03-31 | $91.00K 10-Q · filed 2020-11-10 | |||
| 2018-12-31 | $64.00K 10-K · filed 2020-03-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |